Skip to main content

Dave Muoio

By Dave Muoio | 04:04 pm | April 01, 2021
Former CEO Ed Cox tells the story of Dthera Sciences and outlines how the digital therapeutics landscape has shifted since his company's heyday.
By Dave Muoio | 12:11 pm | April 01, 2021
The virtual care startup will also look to accept additional health insurance carriers going forward.
By Dave Muoio | 03:51 pm | March 31, 2021
The company hopes to maintain its momentum after a year of substantial growth.
By Dave Muoio | 02:28 pm | March 31, 2021
The deal is valued at about $194 million and will drive about a third of the telemedicine company's expected revenue moving forward.
By Dave Muoio | 03:52 pm | March 30, 2021
The Oxehealth Vital Signs system is installed in a patient's hospital room, where it can spot-measure pulse, heart, respiratory and breathing rates with no physical contact.
By Dave Muoio | 04:07 pm | March 29, 2021
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
By Dave Muoio | 01:28 pm | March 29, 2021
The San Clemente, California-based company is aiming to expand its payer- and employer-focused care platform with the funds.
By Dave Muoio | 03:57 pm | March 25, 2021
Published yesterday in PLoS ONE, the data suggests an alternative to the six-minute walk test often conducted in clinics to measure functional capacity.
By Dave Muoio | 01:31 pm | March 25, 2021
The nearly 14-year-old company hopes to raise $75 million to support its implanted, closed-loop seizure prevention system.
By Dave Muoio | 04:06 pm | March 24, 2021
Also: Boston Medical Center releases free app for clinicians treating OUD; ClearUP's OTC sinus relief device wins expanded indication.